Subscribe
Be the first with the news that moves the market- Defence Therapeutics (DTC) was issued a patent for its Accum-based vaccine enhancer technology platform
- Accum contains a “drop-in” ingredient to boost immunogenicity and performance of cell-based or protein subunit vaccines
- This could bolster Defences patent portfolio and help the tea to advance its own novel clinical vaccine candidates
- Defence Therapeutics (DTC) opened trading at $3.80 per share
In 2021, the global vaccines market was valued at $61.04 billion and is projected to grow to $125.49 billion in 2028 at a CAGR of 10.8 per cent according to Fortune Business Insights.
This is good news for Defence Therapeutics (CSE:DTC), who was just issued a patent for its Accum-based vaccine enhancer technology platform.
The Vancouver-based biopharmaceutical company develops novel immune-oncology vaccines and drug delivery technologies including Antibody Drug Conjugates (ADCs).
Accum contains a “drop-in” ingredient to boost immunogenicity and performance of cell-based or protein subunit vaccines, including both prophylactic and therapeutic vaccines in the fields of cancer and infectious diseases.
In a media release on the news of this patent, the company pointed to its ability to improve activation of antigen-specific CD4 and CD8 T cell responses upon simple admixture with an antigen paves the way for highly potent next-generation vaccines having reduced antigen doses.
The patent no. 11,612,651 was issued by the United States Patent and Trademark Office (USPTO).
This could bolster Defence’s patent portfolio and help the tea to advance its own novel clinical vaccine candidates.
Due to the breadth of coverage and ease of implementation of the technology, it would also create new licensing and partnering opportunities. The company added that its enhancer technology can increase the quality of antigen presentation by immune cells and it is being explored to improve upon existing vaccines and clinically-validated antigen candidates, such as by reducing antigen dose, thereby lowering manufacturing costs and potentially diminishing patient adverse reactions.
Defence Therapeutics CEO, Sebastien Plouffe called the rapid granting of this broad patent by the USPTO a testament to the innovative nature and quality of the underlying science behind his company’s Accum technology.
“The Company has plans to leverage the USPTO’s approval to secure global patent protection in all key vaccine markets, including infectious diseases and cancers, and to capitalize notably on the current mRNA boom in the vaccine development market.”
Defence’s current “vaccines in development programs” using its Accum technology includes its ARM vaccine targeting solid cancer tumors, the AccuTOX small molecule targeting melanoma, breast and lung cancers, AccuVAC-PT007, a prophylactic and therapeutic protein-based vaccine targeting cervical cancer, as well as mRNA vaccines for multiple indications. Defence also has positive validation on vaccines developed for certain infectious disease.
Defence Therapeutics (DTC) opened trading at $3.80 per share and is up 36.5 per cent year to date.
For full disclaimer information, click here.
